Hemispherx BioPharma, Inc Share Price Nyse
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
05-15 | AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 172K 13.47M | Sales 2025 * | 1.78M 139M | Capitalization | 18.1M 1.41B |
---|---|---|---|---|---|
Net income 2024 * | -22M -1.72B | Net income 2025 * | -25M -1.95B | EV / Sales 2024 * | 105 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 10.2 x |
P/E ratio 2024 * |
-0.8
x | P/E ratio 2025 * |
-0.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.07% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 03/04/22 |
Chief Tech/Sci/R&D Officer | - | 31/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 27/03/23 |
William Mitchell
CHM | Chairman | 89 | 30/06/98 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
1st Jan change | Capi. | |
---|---|---|
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |